EM-84403
19 January 2022
—
Managing adverse events associated with cellular therapies
MM~Multiple Myeloma~myelomaconnect~RRMM
EM-56870
25 January 2022
—
What are the qualification criteria for CAR T-cell therapy for patients with multiple myeloma: Which patients to refer and when?
MM~Multiple Myeloma~myelomaconnect~RRMM
EM-78373
27 January 2022
—
Challenges in CLL: managing cardiac morbidities in patients with CLL
challengesincll~CLL
EM-78428
1 February 2022
—
Sequencing options today and in the future for patients with relapsed/refractory multiple myeloma
MM~Multiple Myeloma~myelomaconnect~RRMM
EM-78378
15 February 2022
—
What is the role of MRD assessment in multiple myeloma?
MM~Multiple Myeloma~myelomaconnect
EM-84231
22 February 2022
—
Differences between CAR T-cell constructs and targets: What do we have today and what is coming?
MM~Multiple Myeloma~myelomaconnect~RRMM
EM-78380
24 February 2022
—
Is ASCT still the standard of care in fit patients with newly-diagnosed multiple myeloma?
MM~Multiple Myeloma~myelomaconnect~NDMM
EM-78382
1 March 2022
—
Challenges in CLL: Using biology to guide first-line treatment
challengesincll~CLL
EM-78433